Gainers

• Shuttle Pharmaceuticals (NASDAQ:SHPH) shares moved upwards by 66.9% to $6.31 during Thursday's after-market session. The company's market cap stands at $2.1 million.
• INVO Fertility (NASDAQ:IVF) stock increased by 20.16% to $1.49. The company's market cap stands at $2.3 million. As per the press release, Q1 earnings came out 3 days ago.
• BiomX (AMEX:PHGE) shares moved upwards by 12.86% to $0.45. The market value of their outstanding shares is at $4.9 million.
• GlucoTrack (NASDAQ:GCTK) shares moved upwards by 8.73% to $0.36. The market value of their outstanding shares is at $2.1 million.
• Lakewood-Amedex (NASDAQ:LABT) shares increased by 7.87% to $3.7. The market value of their outstanding shares is at $6.5 million.
• Greenland Mines (NASDAQ:GRML) shares rose 7.09% to $0.22. The company's market cap stands at $34.3 million.

Losers

• Creative Medical Tech (NASDAQ:CELZ) stock fell 22.5% to $1.55 during Thursday's after-market session. The market value of their outstanding shares is at $7.3 million.
• Catheter Precision (AMEX:VTAK) shares decreased by 9.1% to $1.1. The company's market cap stands at $3.2 million.
• Atlantic International (NASDAQ:ATLN) shares fell 8.66% to $0.95. The market value of their outstanding shares is at $59.4 million. The company's, Q1 earnings came out 3 days ago.
• Pomdoctor (NASDAQ:POM) stock declined by 8.46% to $1.3. The company's market cap stands at $158.5 million.
• Tenon Medical (NASDAQ:TNON) shares decreased by 6.46% to $0.46. The company's market cap stands at $4.7 million.
• Eikon Therapeutics (NASDAQ:EIKN) shares decreased by 6.17% to $9.24. The company's market cap stands at $521.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.